HYDERABAD, India & PRINCETON, N.J., September 07, 2022--Dr. Reddy’s Laboratories Ltd. today announced the launch, in the U.S. market, of Lenalidomide Capsules.
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) and its subsidiary Intercept Pharma Europe Limited settled patent litigation with Dr. Reddy’s Laboratories Ltd (NYSE: RDY). The litigation concerns the submission by Dr. Reddy’s of an Abbreviated New Drug Application seeking approval to market a generic version of Ocaliva (obeticholic acid) 5 mg and 10 mg tablets before the expiration of the Company’s U.S. patents. Related: Intercept Shares Jump After Reissuing Annual Guidance. Under the terms of the
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.